James E Polli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4920910/publications.pdf

Version: 2024-02-01

137 papers	5,504 citations	101543 36 h-index	91884 69 g-index
140 all docs	140 docs citations	140 times ranked	4992 citing authors

#	Article	IF	Citations
1	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate. Journal of Pharmaceutical Sciences, 2022, 111, 2-13.	3.3	6
2	Evaluation of Excipient Risk in BCS Class I and III Biowaivers. AAPS Journal, 2022, 24, 20.	4.4	16
3	Lack of association between generic brittleness and neuropsychiatric measures in patients with epilepsy. Epilepsy and Behavior, 2022, 128, 108587.	1.7	0
4	Prediction of In Vitro Drug Dissolution into Fed-state Biorelevant Media: Contributions of Solubility Enhancement and Relatively Low Colloid Diffusivity. European Journal of Pharmaceutical Sciences, 2022, 173, 106179.	4.0	5
5	Sources of dissolution variability into biorelevant media. International Journal of Pharmaceutics, 2022, 620, 121745.	5.2	2
6	Prediction of in vitro drug dissolution into fasted-state biorelevant media: Contributions of solubility enhancement and relatively low colloid diffusivity. European Journal of Pharmaceutical Sciences, 2022, 174, 106210.	4.0	6
7	Lack of an Effect of Polysorbate 80 on Intestinal Drug Permeability in Humans. Pharmaceutical Research, 2022, 39, 1881-1890.	3.5	7
8	Comparison of a single pharmaceutical surfactant versus intestinal biorelevant media for etravirine dissolution: Role and impact of micelle diffusivity. International Journal of Pharmaceutics, 2022, 624, 122015.	5.2	0
9	Characterization of Dissolution-Permeation System using Hollow Fiber Membrane Module and Utility to Predict in Vivo Drug Permeation Across BCS Classes. Journal of Pharmaceutical Sciences, 2022, 111, 3075-3087.	3.3	3
10	Similarity of dissolution profiles from biorelevant media: Assessment of interday repeatability, interanalyst repeatability, and interlaboratory reproducibility using ibuprofen and ketoconazole tablets. European Journal of Pharmaceutical Sciences, 2021, 156, 105573.	4.0	14
11	Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate. Molecular Pharmaceutics, 2021, 18, 1544-1557.	4.6	5
12	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride. Journal of Pharmaceutical Sciences, 2021, 110, 1513-1526.	3.3	8
13	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine. Journal of Pharmaceutical Sciences, 2021, 110, 1935-1947.	3.3	10
14	3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration. Clinical and Translational Science, 2021, 14, 1659-1680.	3.1	77
15	Research and Education Needs for Complex Generics. Pharmaceutical Research, 2021, 38, 1991-2001.	3.5	7
16	Metformin Disrupts Bile Acid Efflux by Repressing Bile Salt Export Pump Expression. Pharmaceutical Research, 2020, 37, 26.	3.5	16
17	ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. Molecular Pharmaceutics, 2020, 17, 361-372.	4.6	13
18	The effects of spray drying, HPMCAS grade, and compression speed on the compaction properties of itraconazole-HPMCAS spray dried dispersions. European Journal of Pharmaceutical Sciences, 2020, 155, 105556.	4.0	12

#	Article	IF	Citations
19	Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. Pharmaceutics, 2020, 12, 988.	4.5	12
20	Characterization of Grades of HPMCAS Spray Dried Dispersions of Itraconazole Based on Supersaturation Kinetics and Molecular Interactions Impacting Formulation Performance. Pharmaceutical Research, 2020, 37, 192.	3.5	13
21	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride. Journal of Pharmaceutical Sciences, 2020, 109, 2654-2675.	3.3	7
22	Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy. Pharmaceutical Research, 2020, 37, 60.	3.5	1
23	Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy. Epilepsy and Behavior, 2020, 105, 106936.	1.7	3
24	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate. Journal of Pharmaceutical Sciences, 2020, 109, 1846-1862.	3.3	10
25	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron. Journal of Pharmaceutical Sciences, 2019, 108, 3157-3168.	3.3	5
26	Utility of Films to Anticipate Effect of Drug Load and Polymer on Dissolution Performance from Tablets of Amorphous Itraconazole Spray-Dried Dispersions. AAPS PharmSciTech, 2019, 20, 331.	3.3	14
27	Fast liquid chromatography-tandem mass spectrometry method for simultaneous determination of eight antiepileptic drugs and an active metabolite in human plasma using polarity switching and timed selected reaction monitoring. Journal of Pharmaceutical and Biomedical Analysis, 2019, 176, 112816.	2.8	14
28	Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatographyâ€“Inductively Coupled Plasmaâ€“Mass Spectrometric Approach. Molecular Pharmaceutics, 2019, 16, 1272-1281.	4.6	14
29	Pigâ€gene mutation database. Environmental and Molecular Mutagenesis, 2019, 60, 759-762.	2.2	15
30	A 19F magnetic resonance imaging-based diagnostic test for bile acid diarrhea. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2019, 32, 163-171.	2.0	3
31	Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy. Epilepsy and Behavior, 2019, 90, 197-203.	1.7	7
32	Indinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1). Pharmaceutical Research, 2018, 35, 14.	3.5	5
33	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride. Journal of Pharmaceutical Sciences, 2018, 107, 1761-1772.	3.3	5
34	Attenuated Accumulation of Novel Fluorine (¹⁹F)-Labeled Bile Acid Analogues in Gallbladders of Fibroblast Growth Factor-15 (FGF15)-Deficient Mice. Molecular Pharmaceutics, 2018, 15, 4827-4834.	4.6	4
35	Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). Pharmaceutical Research, 2018, 35, 243.	3.5	24
36	Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharmaceutical Research, 2018, 35, 204.	3.5	22

#	Article	IF	Citations
37	Authorized Generic Drugs: an Overview. AAPS PharmSciTech, 2018, 19, 2450-2458.	3.3	5
38	Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice. Oncotarget, 2018, 9, 25572-25585.	1.8	20
39	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril. Journal of Pharmaceutical Sciences, 2017, 106, 1933-1943.	3.3	27
40	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate. Journal of Pharmaceutical Sciences, 2017, 106, 2930-2945.	3.3	31
41	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Folic Acid. Journal of Pharmaceutical Sciences, 2017, 106, 3421-3430.	3.3	19
42	Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey. Annals of the New York Academy of Sciences, 2017, 1407, 26-38.	3.8	9
43	Multidrug and toxin extrusion proteins mediate cellular transport of cadmium. Toxicology and Applied Pharmacology, 2017, 314, 55-62.	2.8	19
44	Reply to â€œOn the Effect of Common Excipients on the Oral Absorption of Class 3 Drugsâ€• Journal of Pharmaceutical Sciences, 2016, 105, 1355-1357.	3.3	5
45	Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir. Journal of Pharmaceutical Sciences, 2016, 105, 996-1005.	3.3	43
46	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. Journal of Pharmaceutical Sciences, 2016, 105, 1362-1369.	3.3	17
47	Prediction of positive food effect: Bioavailability enhancement of BCS class II drugs. International Journal of Pharmaceutics, 2016, 506, 110-115.	5.2	22
48	Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid. Journal of Pharmaceutical Sciences, 2016, 105, 3243-3255.	3.3	23
49	Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport. Journal of Visualized Experiments, 2016, , .	0.3	6
50	Release of levetiracetam from extended-release tablets that appear intact in patient stool. Seizure: the Journal of the British Epilepsy Association, 2016, 40, 7-9.	2.0	2
51	Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. Drug Metabolism and Disposition, 2016, 44, 489-494.	3.3	18
52	Generic lamotrigine versus brandâ€name <scp>Lamictal</scp> bioequivalence in patients with epilepsy: A field test of the <scp>FDA</scp> bioequivalence standard. Epilepsia, 2015, 56, 1415-1424.	5.1	68
53	Gordon L. Amidon: Very Sustained Drug Absorption. Journal of Pharmaceutical Sciences, 2015, 104, 2650-2663.	3.3	1
54	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine. Journal of Pharmaceutical Sciences, 2015, 104, 3289-3298.	3.3	31

#	Article	IF	Citations
55	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam. Journal of Pharmaceutical Sciences, 2015, 104, 2676-2687.	3.3	23
56	Synthesis and Evaluation of Bile Acidâ€“Ribavirin Conjugates as Prodrugs to Target the Liver. Journal of Pharmaceutical Sciences, 2015, 104, 2864-2876.	3.3	19
57	Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets. Molecular Pharmaceutics, 2015, 12, 2436-2443.	4.6	25
58	Quantification of Lamotrigine in Patient Plasma Using a Fast Liquid Chromatographyâ€“Tandem Mass Spectrometry Method With Backflush Technology. Therapeutic Drug Monitoring, 2015, 37, 188-197.	2.0	8
59	Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. Carcinogenesis, 2015, 36, 1193-1200.	2.8	49
60	A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide. International Journal of Pharmaceutics, 2015, 478, 88-95.	5.2	25
61	Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. European Journal of Pharmaceutical Sciences, 2015, 66, 1-9.	4.0	29
62	Considerations for a Pediatric Biopharmaceutics Classification System (BCS): Application to Five Drugs. AAPS PharmSciTech, 2014, 15, 601-611.	3.3	35
63	The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance. Journal of Pharmaceutical Sciences, 2014, 103, 3377-3397.	3.3	60
64	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fluconazole. Journal of Pharmaceutical Sciences, 2014, 103, 3843-3858.	3.3	29
65	Mechanistic interpretation of conventional Michaelisâ€“Menten parameters in a transporter system. European Journal of Pharmaceutical Sciences, 2014, 64, 44-52.	4.0	15
66	Structural Requirements of the Human Sodium-Dependent Bile Acid Transporter (hASBT): Role of 3- and 7-OH Moieties on Binding and Translocation of Bile Acids. Molecular Pharmaceutics, 2014, 11, 588-598.	4.6	5
67	In Vivo Performance of a Novel Fluorinated Magnetic Resonance Imaging Agent for Functional Analysis of Bile Acid Transport. Molecular Pharmaceutics, 2014, 11, 1575-1582.	4.6	20
68	Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver. International Journal of Pharmaceutics, 2014, 475, 597-604.	5.2	26
69	Design and Evaluation of a Novel Trifluorinated Imaging Agent for Assessment of Bile Acid Transport Using Fluorine Magnetic Resonance Imaging. Journal of Pharmaceutical Sciences, 2014, 103, 3782-3792.	3.3	10
70	Design and Characterization of a Novel Fluorinated Magnetic Resonance Imaging Agent for Functional Analysis of Bile Acid Transporter Activity. Pharmaceutical Research, 2013, 30, 1240-1251.	3.5	9
71	The solute carrier family 10 (SLC10): Beyond bile acid transport. Molecular Aspects of Medicine, 2013, 34, 252-269.	6.4	145
72	Structureâ€“Activity Relationship for FDA Approved Drugs As Inhibitors of the Human Sodium Taurocholate Cotransporting Polypeptide (NTCP). Molecular Pharmaceutics, 2013, 10, 1008-1019.	4.6	86

#	Article	IF	Citations
73	Phrygian Cap Appearance of a Mouse Gallbladder on Magnetic Resonance Imaging. Journal of Veterinary Science & Medical Diagnosis, 2013, 02, .	0.0	0
74	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Ketoprofen. Journal of Pharmaceutical Sciences, 2012, 101, 3593-3603.	3.3	70
75	A Substrate Pharmacophore for the Human Organic Cation/Carnitine Transporter Identifies Compounds Associated with Rhabdomyolysis. Molecular Pharmaceutics, 2012, 9, 905-913.	4.6	16
76	Putative Irreversible Inhibitors of the Human Sodium-Dependent Bile Acid Transporter (hASBT;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Pharmaceutical Research, 2012, 29, 1821-1831.	3.5	6
77	Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. European Journal of Pharmaceutical Sciences, 2012, 46, 86-99.	4.0	30
78	Identification of Novel Nonsteroidal Compounds as Substrates or Inhibitors of hASBT. Journal of Pharmaceutical Sciences, 2012, 101, 116-126.	3.3	8
79	Synthesis and In Vitro Evaluation of Gabapentin Prodrugs that Target the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT). Journal of Pharmaceutical Sciences, 2011, 100, 1184-1195.	3.3	33
80	Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2. Journal of Pharmaceutical Sciences, 2011, 100, 3802-3816.	3.3	16
81	Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally Sampled Pharmacophore Approach. Current Computer-Aided Drug Design, 2011, 7, 10-22.	1.2	210
82	In Vivo Magnetic Resonance Imaging to Detect Biliary Excretion of 19F-Labeled Drug in Mice. Drug Metabolism and Disposition, 2011, 39, 736-739.	3.3	6
83	Comparison of Drug Permeabilities and BCS Classification: Three Lipid-Component PAMPA System Method versus Caco-2 Monolayers. AAPS Journal, 2010, 12, 238-241.	4.4	38
84	Quantitative Structure Activity Relationship for Inhibition of Human Organic Cation/Carnitine Transporter. Molecular Pharmaceutics, 2010, 7, 2120-2131.	4.6	31
85	Impact of Biopharmaceutics Classification System-Based Biowaivers. Molecular Pharmaceutics, 2010, 7, 1539-1544.	4.6	42
86	Effects of Commonly Used Excipients on the Expression of CYP3A4 in Colon and Liver Cells. Pharmaceutical Research, 2010, 27, 1703-1712.	3.5	27
87	Reliability of Inhibition Models to Correctly Identify Type of Inhibition. Pharmaceutical Research, 2010, 27, 2433-2445.	3.5	15
88	Identification of inhibitor concentrations to efficiently screen and measure inhibition Ki values against solute carrier transporters. European Journal of Pharmaceutical Sciences, 2010, 41, 43-52.	4.0	22
89	Why we should be vigilant: Drug cytotoxicity observed with in vitro transporter inhibition studies. Biochemical Pharmacology, 2010, 80, 1087-1092.	4.4	11
90	Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT. International Journal of Pharmaceutics, 2010, 396, 111-118.	5.2	24

#	Article	IF	Citations
91	Targeting Drug Transporters â€“ Combining In Silico and In Vitro Approaches to Predict In Vivo. Methods in Molecular Biology, 2010, 637, 65-103.	0.9	17
92	Structural Requirements of the ASBT by 3D-QSAR Analysis Using Aminopyridine Conjugates of Chenodeoxycholic Acid. Bioconjugate Chemistry, 2010, 21, 2038-2048.	3.6	15
93	Molecular Switch Controlling the Binding of Anionic Bile Acid Conjugates to Human Apical Sodium-Dependent Bile Acid Transporter. Journal of Medicinal Chemistry, 2010, 53, 4749-4760.	6.4	23
94	Structural Determinants for Transport across the Intestinal Bile Acid Transporter Using C-24 Bile Acid Conjugates. Molecular Pharmaceutics, 2010, 7, 2240-2254.	4.6	22
95	Uptake of Pramipexole by Human Organic Cation Transporters. Molecular Pharmaceutics, 2010, 7, 1342-1347.	4.6	27
96	Inhibition Requirements of the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT) Using Aminopiperidine Conjugates of glutamyl-Bile Acids. Pharmaceutical Research, 2009, 26, 1665-1678.	3.5	26
97	Novel Inhibitors of Human Organic Cation/Carnitine Transporter (hOCTN2) via Computational Modeling and In Vitro Testing. Pharmaceutical Research, 2009, 26, 1890-1900.	3.5	36
98	Computational Models for Drug Inhibition of the Human Apical Sodium-Dependent Bile Acid Transporter. Molecular Pharmaceutics, 2009, 6, 1591-1603.	4.6	89
99	The Use of BDDCS in Classifying the Permeability of Marketed Drugs. Pharmaceutical Research, 2008, 25, 483-488.	3.5	124
100	In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms. AAPS Journal, 2008, 10, 289-299.	4.4	117
101	Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond. AAPS Journal, 2008, 10, 373-379.	4.4	55
102	Method to Screen Substrates of Apical Sodium-Dependent Bile Acid Transporter. AAPS Journal, 2008, 10, 596-605.	4.4	16
103	Impact of Impurity on Kinetic Estimates from Transport and Inhibition Studies. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 296-305.	2.5	6
104	Bias in Estimation of Transporter Kinetic Parameters from Overexpression Systems: Interplay of Transporter Expression Level and Substrate Affinity. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 133-144.	2.5	32
105	Evaluation of a novel tablet splitter. Journal of the American Pharmacists Association: JAPhA, 2007, 47, 185-187.	1.5	1
106	Computational Models to Assign Biopharmaceutics Drug Disposition Classification from Molecular Structure. Pharmaceutical Research, 2007, 24, 2249-2262.	3.5	61
107	Chemical Substituent Effect on Pyridine Permeability and Mechanistic Insight from Computational Molecular Descriptors. Molecular Pharmaceutics, 2006, 3, 745-755.	4.6	10
108	Rapid Identification of P-glycoprotein Substrates and Inhibitors. Drug Metabolism and Disposition, 2006, 34, 1976-1984.	3.3	136

#	Article	IF	Citations
109	Apical Sodium Dependent Bile Acid Transporter (ASBT, SLC10A2):Â A Potential Prodrug Target. Molecular Pharmaceutics, 2006, 3, 223-230.	4.6	150
110	Influence of Charge and Steric Bulk in the C-24 Region on the Interaction of Bile Acids with Human Apical Sodium-Dependent Bile Acid Transporter. Molecular Pharmaceutics, 2006, 3, 282-292.	4.6	24
111	Interaction of Native Bile Acids with Human Apical Sodium-Dependent Bile Acid Transporter (hASBT): Influence of Steroidal Hydroxylation Pattern and C-24 Conjugation. Pharmaceutical Research, 2006, 23, 1451-1459.	3.5	50
112	Lipid composition effect on permeability across PAMPA. European Journal of Pharmaceutical Sciences, 2006, 29, 259-268.	4.0	50
113	Ion pair-mediated transport of metoprolol across a three lipid-component PAMPA system. Journal of Controlled Release, 2006, 116, 50-57.	9.9	25
114	Development of Stably Transfected Monolayer Overexpressing the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT). Pharmaceutical Research, 2005, 22, 1269-1280.	3.5	41
115	Surfactant-mediated dissolution: Contributions of solubility enhancement and relatively low micelle diffusivity. Journal of Pharmaceutical Sciences, 2004, 93, 2064-2075.	3.3	116
116	Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate. Molecular Pharmaceutics, 2004, 1, 40-48.	4.6	110
117	Human Intestinal Cellular Characteristics and Drug Permeability. , 2004, , 163-180.		2
118	Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharmaceutical Research, 2003, 20, 757-764.	3.5	63
119	Characterization of Dexloxiglumide in vitro Biopharmaceutical Properties and Active Transport. Journal of Pharmaceutical Sciences, 2003, 92, 1968-1980.	3.3	11
120	Weight Uniformity of Split Tablets Required by a Veterans Affairs Policy. Journal of Managed Care Pharmacy, 2003, 9, 401-407.	2.2	39
121	Novel Metrics to Compare Dissolution Profiles. Pharmaceutical Development and Technology, 2002, 7, 257-265.	2.4	6
122	Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. European Journal of Pharmaceutical Sciences, 2002, 16, 237-246.	4.0	439
123	Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceutical Research, 2002, 19, 921-925.	3.5	460
124	Effect of Common Excipients on Caco-2 Transport of Low-Permeability Drugs. Journal of Pharmaceutical Sciences, 2001, 90, 1776-1786.	3.3	167
125	Novel direct curve comparison metrics for bioequivalence. , 2001, 18, 734-741.		24
126	Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. International Journal of Pharmaceutics, 2000, 200, 41-51.	5.2	77

#	Article	IF	Citations
127	Influence of passive permeability on apparent P-glycoprotein kinetics. Pharmaceutical Research, 2000, 17, 1456-1460.	3.5	111
128	Prediction of dissolutionâ€“absorption relationships from a dissolution/Caco-2 system. International Journal of Pharmaceutics, 1999, 177, 117-125.	5.2	73
129	Dependence of In Vitro-In Vivo Correlation Analysis Acceptability on Model Selections. Pharmaceutical Development and Technology, 1999, 4, 89-96.	2.4	9
130	Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system. AAPS PharmSci, 1999, 1, 27-38.	1.3	52
131	Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities. , 1998, 15, 47-52.		36
132	in Vitro-in Vivo Relationships of Several â€œImmediateâ€•Release Tablets Containing a Low Permeability Drug. Advances in Experimental Medicine and Biology, 1997, 423, 191-198.	1.6	20
133	Methods to Compare Dissolution Profiles and a Rationale for Wide Dissolution Specifications for Metoprolol Tartrate tabletsâ€. Journal of Pharmaceutical Sciences, 1997, 86, 690-700.	3.3	266
134	Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence. , 1997, 14, 1363-1369.		22
135	â€˜PAVLOVIANâ€™ FOOD EFFECT ON THE ENTEROHEPATIC RECIRCULATION OF PIROXICAM. , 1996, 17, 635-641.		16
136	Novel Approach to the Analysis of in Vitroâ€“in Vivo Relationships**Presented in part at the Ninth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, San Diego, CA, November 1994.. Journal of Pharmaceutical Sciences, 1996, 85, 753-760.	3.3	76
137	Methods to Compare Dissolution Profiles. Drug Information Journal, 1996, 30, 1113-1120.	0.5	36